News Releases

Date Title and Summary
Toggle Summary electroCore to Join Russell Microcap® Index
ROCKAWAY, NJ , June 16, 2021 (GLOBE NEWSWIRE) --   electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today the addition of its stock to the broad-market Russell Microcap ® Index after its 2021 annual reconstitution, effective after the open of trading on
Toggle Summary electroCore Completes Sale of $1.4 Million of NJ NOL Tax Benefits
ROCKAWAY, NJ , June 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of $1.4 million of its available tax benefits through the New Jersey Economic Development Authority’s Technology
Toggle Summary electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’s Disease Patients
ROCKAWAY, N.J. , June 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper, entitled “Non-Invasive Vagus Nerve Stimulation Improves Clinical and Molecular Biomarkers of Parkinson’s
Toggle Summary electroCore to Present at Investor Conferences in June
ROCKAWAY, NJ , May 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today that its management team will present a several investor conferences during the month of June. The conferencing details are as follows: Summer
Toggle Summary electroCore Announces First Quarter 2021 Financial Results
Record First quarter 2021 net sales of $1.2 million , increased 64% over first quarter 2020 and 30% sequentially Company to host a conference call and webcast today, May 6, 2021 at 4:30 pm ET ROCKAWAY, N.J. , May 06, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.
Toggle Summary electroCore, Inc. Announces U.S. Department of Veterans Affairs Study of gammaCore Sapphire™ (Non-Invasive Vagus Nerve Stimulator) for the Treatment of Post-Traumatic Headache
ROCKAWAY, NJ , May 04, 2021 (GLOBE NEWSWIRE) -- -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the U.S. Department of Veterans Affairs is starting an investigator-initiated study of the use of gammaCore Sapphire TM non-invasive vagus nerve
Toggle Summary electroCore to Announce First Quarter 2021 Financial Results on Thursday, May 6
ROCKAWAY, NJ , April 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2021 after the close of the market on Thursday, May 6, 2021 .
Toggle Summary electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders
ROCKAWAY, NJ , April 26, 2021 (GLOBE NEWSWIRE) --  -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Johns Hopkins University School of Medicine is starting an investigator-initiated trial of non-invasive vagus nerve stimulation (nVNS)
Toggle Summary electroCore, Inc. Announces Exclusive Distribution Agreement with East Agency For Qatar
ROCKAWAY, NJ , April 20, 2021 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with East Agency to serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve
Toggle Summary electroCore Announces Publication in Nature Reviews: Neurology Highlighting the Role of Non-Invasive Vagus Nerve Stimulation (nVNS) as an Emerging Treatment for Cluster Headache
ROCKAWAY, NJ , April 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Cluster headache pathophysiology — insights from current and emerging treatments,” by Drs.